Reported frequency of COVID-19 in patients with RMDs treated with antimalarials
| Total confirmed cases | Cases on previous HCQ/CQ (% total) | Severe course* if on previous HCQ/CQ (%) | |
| Avouac et al 8 | 3 | 0 | – |
| Bozzalla Cassione et al 10 | 4 | 3 (75) | 1 (33) |
| Benoy et al 3 | 27 | 5 (19) | NR |
| D’Silva et al 11 | 52 | 9 (17) | 5 (56) |
| Favalli et al 2† | 6 | 1 (17) | 1 (100) |
| Gianfrancesco et al 13‡ | 600 | 130 (22) | 66 (51) |
| Haberman et al 14 | 50 | 8 (16) | 3 (38) |
| Mathian et al 15 | 17 | 17 (100) | 14 (82) |
| Michelena et al 4 | 11 | 0 | – |
| Monti et al 9 | 4 | 1 (25) | 0 |
| Romão et al 1 | 2 | 2 (100) | 0 |
| Sanchez-Piedra et al 7 | 41 | 4 (10) | NR |
| Wallace et al 16 | 31 | 4 (13) | 3 (75) |
| Ye et al 6 | 21 | 6 (29) | 6 (100) |
| Total | 869 | 190 (22) | 99 (55)§ |
*Defined as those requiring hospitalisation.
†Data also include patients reported by Favalli et al 5 in a separate publication.
‡Data also include patients reported by Konig et al 12 in a separate publication.
§Percentage calculated based on patients with available data (n=181).
CQ, chloroquine; HCQ, hydroxychloroquine; NR, not reported.